Bio-Techne (NASDAQ:TECH) Shares Unloaded Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently sold shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on January 28th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of Trimble (NASDAQ:TRMB) on 1/28/2026.
• Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 1/28/2026.
• Sold $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 1/23/2026.
• Sold $1,001 – $15,000 in shares of Somnigroup International (NYSE:SGI) on 1/22/2026.
• Sold $1,001 – $15,000 in shares of Wabtec (NYSE:WAB) on 1/22/2026.
• Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 1/15/2026.

Bio-Techne Stock Performance

Shares of Bio-Techne stock opened at $64.63 on Wednesday. The company has a quick ratio of 2.81, a current ratio of 4.22 and a debt-to-equity ratio of 0.15. Bio-Techne Corp has a 52 week low of $46.01 and a 52 week high of $79.28. The firm’s 50 day moving average is $63.15 and its two-hundred day moving average is $59.14. The firm has a market capitalization of $10.07 billion, a P/E ratio of 131.90, a P/E/G ratio of 4.50 and a beta of 1.48.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.03. The business had revenue of $295.88 million during the quarter, compared to analysts’ expectations of $290.20 million. Bio-Techne had a net margin of 6.41% and a return on equity of 13.59%. Research analysts forecast that Bio-Techne Corp will post 1.67 EPS for the current fiscal year.

Analyst Ratings Changes

TECH has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft set a $72.00 price objective on shares of Bio-Techne and gave the company a “buy” rating in a research note on Friday, December 12th. Evercore ISI set a $62.00 target price on Bio-Techne and gave the company an “in-line” rating in a report on Monday, January 5th. Benchmark reissued a “buy” rating on shares of Bio-Techne in a research report on Tuesday. Zacks Research lowered Bio-Techne from a “hold” rating to a “strong sell” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Bio-Techne in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Bio-Techne has a consensus rating of “Moderate Buy” and a consensus price target of $70.57.

Institutional Trading of Bio-Techne

Several institutional investors and hedge funds have recently added to or reduced their stakes in TECH. Wellington Management Group LLP increased its holdings in shares of Bio-Techne by 349.8% in the third quarter. Wellington Management Group LLP now owns 5,115,133 shares of the biotechnology company’s stock valued at $284,555,000 after purchasing an additional 3,978,026 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Bio-Techne by 164.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,012,818 shares of the biotechnology company’s stock worth $235,994,000 after purchasing an additional 2,495,328 shares during the period. Invesco Ltd. grew its position in Bio-Techne by 7.7% in the 3rd quarter. Invesco Ltd. now owns 3,946,028 shares of the biotechnology company’s stock valued at $219,518,000 after buying an additional 283,303 shares during the last quarter. Neuberger Berman Group LLC increased its stake in Bio-Techne by 32.3% in the 3rd quarter. Neuberger Berman Group LLC now owns 3,307,116 shares of the biotechnology company’s stock valued at $183,975,000 after buying an additional 807,147 shares during the period. Finally, Mairs & Power Inc. increased its stake in Bio-Techne by 3.4% in the 3rd quarter. Mairs & Power Inc. now owns 2,807,409 shares of the biotechnology company’s stock valued at $156,176,000 after buying an additional 91,031 shares during the period. 98.95% of the stock is owned by hedge funds and other institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.